Author: Pamela Jackson ; Charles Noble ; Michael F. Wendland ; Mitchel S. Berger ; Daryl C. Drummond ; John W. Park ; Michal T. Krauze ; Krystof S. Bankiewicz ; Tracy R. McKnight ; John R. Bringas ; Dimitri B. Kirpotin ; Keelung Hong ; Christoph Mamot ; Ryuta Saito

Drug delivery to brain tumors has long posed a major challenge. Convection-enhanced delivery (CED) has been developed as a drug delivery strategy to overcome this difficulty. Ideally, direct visualization of the tissue distribution of drugs infused by CED would assure successful delivery of therapeutic agents to the brain tumor while minimizing exposure of the normal brain. We previously developed a magnetic resonance imaging (MRI)-based method to visualize the distribution of liposomal agents after CED in rodent brains. In the present study, CED of liposomes was further examined in the non-human primate brain (n = 6). Liposomes containing Gadoteridol, DiI-DS, and rhodamine were infused in corona radiata, putamen nucleus, and brain stem. Volume of distribution was analyzed for all delivery locations by histology and MR imaging. Real-time MRI monitoring of liposomes containing gadolinium allowed direct visualization of a robust distribution. MRI of liposomal gadolinium was highly accurate at determining tissue distribution, as confirmed by comparison with histological results from concomitant administration of fluorescent liposomes. Linear correlation for liposomal infusions between infusion volume and distribution volume was established in all targeted locations. We conclude that an integrated strategy combining liposome/nanoparticle technology, CED, and MRI may provide new opportunities for the treatment of brain tumors. Our ability to directly monitor and to control local delivery of liposomal drugs will most likely result in greater clinical efficacy when using CED in management of patients.

01 Feb 1992·ParasitologyQ3 · MEDICINE

Estimation of relative fecundity inEimeria tenellastrains by a mixed infection method

Q3 · MEDICINE

Article

Author: T. Nakamura ; J. Imose ; H. Kawaguchi ; T. Konishi

SUMMARYThe relative fecundity of populations ofEimeria tenellawas estimated by means of mixed infection using electrophoretic variation of glucose-phosphate isomerases (GPIs) as a genetic marker. A decoquinate-resistant strain with GPI-9 isozyme (DR-NIAH), a decoquinate-sensitive one with GPI-1 (DS-Iwate), and three decoquinate-resistant lines (No. 3, 4, and 5) derived from cross-fertilization between DR-NIAH and DS-Iwate, were used. The GPI phenotypes of the No. 3 and No. 4 lines are GPI-9, and that of No. 5 is GPI-1. Mixed infection experiments were performed between DR-NIAH and DS-Iwate, No. 3 and No. 5, and No. 4 and No. 5. DR-NIAH was predominant over DS-Iwate in the mixed infection, whereas, in single infections, the total oocyst output of DR-NIAH was similar to or less than that of DS-Iwate. Among three lines, No. 4 was predominant over No. 5, and No. 5 was predominant over No. 3 in the mixed infection. Relative fecundity between No. 3 and No. 5 and their patterns of oocyst output in single infections were similar to those in the mixed infection. In contrast, No. 5 produced more oocysts than No. 4 in single infections, suggesting that the oocyst production in the mixed infection may be influenced by the mutual interference or competition between the populations ofE. tenellain the chicken caeca.

01 Dec 1978·Journal of obstetrics and gynaecology of India

Endocrinal and target organ changes caused by injection of small doses of progestogens.

Article

Author: Philips, F S ; Prema, K

100 Deals associated with Estradiol Valerate/Testosterone Enanthate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	G03EA02	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ovarian Insufficiency	JP	Fuji Pharma Co., Ltd.	28 Feb 2008
Andropause	JP	Mochida Pharmaceutical Co., Ltd.	24 Mar 1980
Osteoporosis	JP	Mochida Pharmaceutical Co., Ltd.	24 Mar 1980
Ovarian Diseases	JP	Mochida Pharmaceutical Co., Ltd.	24 Mar 1980

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis